Drug intelligence / Profile preview

GO401

Development stage: Preclinical
Lead developer: GeneSail Biotech
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral, Intraperitoneal

Overview

GO401 is an investigational oncolytic vaccinia virus being developed by GeneSail Biotech for the treatment of solid tumors. Developed using the company's proprietary OVBody technology platform, GO401 is designed to selectively infect, replicate within, and destroy tumor cells while sparing healthy tissue. The candidate is currently in preclinical development, having reached the pharmacological research stage.

Beyond the preview

Go deeper on GO401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GO401.

Explore the full profile